"10.1371_journal.pone.0024395","plos one","2011-09-16T00:00:00Z","Weiliang Qiu; Michael H Cho; John H Riley; Wayne H Anderson; Dave Singh; Per Bakke; Amund Gulsvik; Augusto A Litonjua; David A Lomas; James D Crapo; Terri H Beaty; Bartolome R Celli; Stephen Rennard; Ruth Tal-Singer; Steven M Fox; Edwin K Silverman; Craig P Hersh; and the ECLIPSE Investigators","Channing Laboratory, Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Division of Pulmonary and Critical Care Medicine, Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; GlaxoSmithKline, Uxbridge, United Kingdom; GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America; Medicines Evaluation Unit, University of Manchester, Manchester, United Kingdom; Department of Thoracic Medicine, Haukeland University Hospital, Institute of Medicine, University of Bergen, Bergen, Norway; Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom; Department of Medicine, National Jewish Health, Denver, Colorado, United States of America; Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America; Division of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America; GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America","Conceived and designed the experiments: WQ JHR EKS CPH. Performed the experiments: WQ MHC JHR WHA DS RT-S SMF EKS CPH. Analyzed the data: WQ MHC CPH. Contributed reagents/materials/analysis tools: JHR WHA DS PB AG DAL JDC BRC SR RT-S SMF EKS AAL. Wrote the paper: WQ THB SR EKS CPH.","The authors have the following competing interests: Dr. Riley, Dr. Anderson, Dr. Tal-Singer, and Dr. Fox are full-time employees of GlaxoSmithKline. The International COPD Genetics Network and The ECLIPSE Study were funded by GlaxoSmithKline. Dr. Singh has received lectures fees, support for conference attendance, advisory board fees and research grants from a range of pharmaceutical companies including GSK, Chiesi Pharmaceuticals, AstraZeneca, Pfizer, CIPLA, Novartis, Forest, MSD, Boehringer and Allmiral. Dr. Lomas has received an educational grant, fees for speaking and acts as a consultant for GSK. Dr. Rennard has consulted for Able Associates, Adelphi Research, APT Pharma/Britnall, Aradigm, AstraZeneca, Boehringer-Ingelheim, Chiesi, CommonHealth, Consult Complete, and COPDForum, and has served on advisory boards for Almirall, Novartis, Nycomed, and Pfizer. Dr. Rennard has received lecture fees from American Thoracic Society, AstraZeneca, Boehringer-Ingelheim, California Allergy Society, and Creative Educational Concept, and has received industry-sponsored grants from AstraZeneca, Biomarck, Centocor, Mpex, and Nabi. Dr. Silverman has received grant support for two studies of COPD genetics and consulting fees from GlaxoSmithKline, and has received consulting fees from Astra-Zeneca. Dr. Silverman has also received honoraria from Wyeth, Bayer, GlaxoSmithKline, and Astra-Zeneca. Dr. Qiu, Dr. Cho, Dr. Bakke, Dr. Gulsvik, Dr. Litonjua, Dr. Crapo, Dr. Beaty, Dr. Celli, and Dr. Hersh do not report any conflicts of interest related to this manuscript. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2011","09","Weiliang Qiu","WQ",18,TRUE,4,9,3,5,TRUE,TRUE,TRUE,1,"18",TRUE
